Business Context and Reporting Period
This Form 8-K was filed by Akebia Therapeutics, Inc. on July 26, 2023. The report addresses Item 5.02 regarding the departure of certain officers and amendments to their separation agreements.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on executive personnel changes and does not contain financial performance data.
Material Changes
The Company amended the retention and separation agreements for two executives originally scheduled to depart on July 28, 2023:
- Michel Dahan (COO): The effective termination date was extended to March 22, 2024. Under certain specified events, this date may extend to September 22, 2024.
- Nicole R. Hadas (SVP, Chief Legal Officer, and Corporate Secretary): The effective termination date was extended to October 6, 2023. Under certain specified events, this date may extend to March 22, 2024.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, outlook, or general risk factors. The primary contingency noted is that the extended termination dates for both executives are subject to "certain specified events" which could further alter the effective dates of their separation.
Investor Verification Checklist
- Verify the specific "specified events" that could trigger further extensions of the termination dates for Mr. Dahan and Ms. Hadas.
- Review the full text of the "Dahan July 2023 Amendment" and "Hadas July 2023 Amendment" expected to be filed as exhibits to the Form 10-Q for the quarter ending June 30, 2023.
- Confirm the impact of these extended departures on the Company's ongoing workforce reduction strategy announced in May 2022.